Explorer les evidences

Palier Gold : evidences validées mécaniquement, avec leur source primaire.

64 evidences · page 2 / 3

31,8 %Among 66 HBsAg-positive patients, 31.8% had HBeAg-positive hepatitis.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations

24 per_100_person_yearsThe incidence rate of serious HIV-related events was 24.0 per 100 person-years among HIV-HBV co-infected patients with baseline HBV-replication > 10,000 copies/mL.

Côte d'Ivoirehépatite B · VIH/sidapublié 2017The American journal of tropical medicine and hygieneeurope_pmcdocument de 7 observationsDOI 10.4269/ajtmh.16-1016

0,8 sensitivityBaseline qHBsAg ≤ 1000 IU/mL had sensitivity of 0.80 and specificity of 0.80 for predicting HBsAg seroclearance at month 36.

Côte d'Ivoirehépatite Bobservé month 36publié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

25,9 %Among 879 participants in the Temprano randomized control trial, 228 (25.9%) were HBV non-immune/vaccinated (HBcAb-negative).

Côte d'Ivoirehépatite Bobservé 2008 and 2015publié 2021Journal of viral hepatitiseurope_pmcdocument de 5 observations

6,04 log_10_copies_per_mLAt ARV-initiation, median HBV-DNA was 6.04 log 10 copies/mL in 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

10 000 copies/mLChronic HBeAg-negative HBV hepatitis phase was defined as HBV DNA >10,000 copies/mL and/or above normal ALT.

Côte d'Ivoirehépatite Bpublié 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument de 4 observations

14,9 %Among HBsAg-positive individuals, 14.9% were also positive for anti-HDV antibody.

Côte d'Ivoirehépatite B · hepatitis Delta virusobservé 2012publié 2017BMC infectious diseaseseurope_pmcdocument de 7 observations

0,9 sensitivityqHBsAg levels ≤ 100 IU/mL at month 12 had sensitivity of 0.90 and specificity of 1.00 for predicting HBsAg seroclearance.

Côte d'Ivoirehépatite Bobservé month 12publié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

28,8 %Twelve S-gene MUPIQHs were identified among 21 of 73 HIV-HBV co-infected patients from Côte d'Ivoire, representing 28.8%.

Côte d'Ivoirehépatite Bpublié 2019Liver international : official journal of the International Association for the Study of teurope_pmcdocument de 4 observationsDOI 10.1111/liv.13975

10 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 10% had occult HBV infection.

Côte d'Ivoirehépatite B · VIH/sidapublié 2010Antiviral therapyeurope_pmcdocument de 7 observations

22 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 22% had signs of cured HBV infection.

Côte d'Ivoirehépatite B · VIH/sidapublié 2010Antiviral therapyeurope_pmcdocument de 7 observations

2,2 log10_copies_per_mlMedian HBV DNA level was 2.2 log(10) copies/ml for patients with occult HBV infection.

Côte d'Ivoirehépatite Bpublié 2010Antiviral therapyeurope_pmcdocument de 7 observations

44,6 %Among 65 HBsAg-positive participants, 29 (44.6%) had HBV-DNA levels > 10,000 copies/mL.

Côte d'Ivoirehépatite Bpublié 2017The American journal of tropical medicine and hygieneeurope_pmcdocument de 7 observationsDOI 10.4269/ajtmh.16-1016

46,3 %Among HBeAg-positive patients, the cumulative proportion with HBeAg seroclearance was 46.3% (n = 14).

Côte d'Ivoirehépatite Bpublié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

1,07 adjusted_IRRHBsAg-positive individuals with HBV-DNA ≥2000 IU/mL had an adjusted incidence rate ratio for mortality of 1.07 (95% CI = 0.01–4.91) at CD4+ counts >500/mm³ compared to HBsAg-negative individuals.

Côte d'Ivoirehépatite B · VIH/sidapublié 2021Antiviral therapyeurope_pmcdocument de 4 observations

2,7 %Among 879 participants in the Temprano randomized control trial, 24 (2.7%) had hepatitis B surface antigen (HBsAg)-positive with HBV DNA ≥ 2,000 IU/ml.

Côte d'Ivoirehépatite Bobservé 2008 and 2015publié 2021Journal of viral hepatitiseurope_pmcdocument de 5 observations

0,57 sensitivityA ≥ 1.0 log10 IU/mL drop in qHBsAg at month 12 had sensitivity of 0.57 and specificity of 1.00 for predicting HBsAg seroclearance at month 36.

Côte d'Ivoirehépatite Bobservé month 36publié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

86,9 %Of 237 HIV-infected patients from two clinical trials, 206 (86.9%) tested positive for hepatitis B surface antigen (HBsAg) using MiniVidas® and had validated serological tests using Architect.

Côte d'Ivoirehépatite B · VIH/sidapublié 2015Diagnostic microbiology and infectious diseaseeurope_pmc

Among 791 HIV-infected patients in West Africa, HBsAg positivity was 7.9% in HIV-1 patients, 7.2% in HIV-1&2 dually reactive patients, and 9.4% in HIV-2 patients.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2012publié 2017BMC infectious diseaseseurope_pmcdocument de 7 observations

13 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 13% were HBsAg-positive.

Côte d'Ivoirehépatite B · VIH/sidapublié 2010Antiviral therapyeurope_pmcdocument de 7 observations

8,6 %Among 879 participants in the Temprano randomized control trial, 76 (8.6%) had hepatitis B surface antigen (HBsAg)-positive with HBV DNA < 2,000 IU/ml.

Côte d'Ivoirehépatite Bobservé 2008 and 2015publié 2021Journal of viral hepatitiseurope_pmcdocument de 5 observations

72,9 %Anti-HBcAb prevalence was 72.9% among 491 adult HIV patients in Abidjan.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations

4,08 log10_IU_per_mLAt ART initiation, median qHBsAg was 4.08 log10 IU/mL among 73 HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2019Liver international : official journal of the International Association for the Study of teurope_pmcdocument de 4 observationsDOI 10.1111/liv.13975

7,8 per_100_person-yearsHBsAg seroconversion incidence among regular male blood donors in Abidjan decreased from 7.8 per 100 person-years in 1992–1994 to 0.2 per 100 person-years in 2010–2012.

Côte d'Ivoirehépatite Bobservé 1992–1994publié 2018Open forum infectious diseaseseurope_pmcdocument de 12 observations

7,27 log10_copies_per_mLAt ART initiation, median HBV-DNA was 7.27 log10 copies/mL among 73 HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2019Liver international : official journal of the International Association for the Study of teurope_pmcdocument de 4 observationsDOI 10.1111/liv.13975

Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.